trending Market Intelligence /marketintelligence/en/news-insights/trending/80rHUrcbwMz27OpUaHT6ag2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Amgen's cancer therapy meets primary endpoint in phase 2 study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Amgen's cancer therapy meets primary endpoint in phase 2 study

Amgen Inc. said the phase 2 trial of Imlygic, in combination with Bristol-Myers Squibb Co.'s Yervoy, met its main goal in an aggressive form of skin cancer.

The study showed that a higher number of unresectable advanced melanoma patients 38.8% experienced a reduction in their tumor compared to 18% for those on Yervoy alone.

Patients on the combination arm were also able to keep their disease at bay for an average of 8.2 months compared to 6.4 months in the Yervoy arm. Amgen said the effect was not statistically significant, but further analysis is pending.